CUSTOM PUBLISHING

Spatial biology is transforming the field of molecular biology by allowing the study of cells within their tissue context. It enables scientists to map tissue architecture and to interrogate cell-to-cell interactions and dependencies. Such granularity is not achieved with any other existing tool.

Spatial biology helps scientists studying oncology, immuno-oncology, immunology, neuroscience, and infectious diseases. In this webinar, the speakers will discuss the benefit of using spatial biology across multiple disciplines. Alexander Klimowicz from Boehringer Ingelheim, Ridgefield, Connecticut, will describe how spatial immunofluorescence can address a broad array of complex questions and help us gain insight into myeloid cell phenotypes associated with Crohn’s disease pathology. Jared Burks from MD Anderson Cancer Center, Houston, Texas, will focus on the spatial distribution of cells in tissues of the tumor microenvironment. Janis Taube from Johns Hopkins University of Medicine, Baltimore, Maryland, will discuss the mapping of solid tumors using multiplexing technology.

In this webinar, viewers will:

• Learn the benefits of performing spatial biology applications for their research
• Discover how to perform immune-cell profiling and correlate cell phenotypes to specific pathological conditions
• Explore how an open platform is crucial to integrate spatial biology for biopharmaceutical translational research
• Hear about the latest trends in spatial biology, from basic research to translational applications
• Have an opportunity to ask questions during the live broadcast.

This webinar will last for approximately 60 minutes.

The dynamics of tumor and immune responses associated with immune checkpoint blockade are unique and complex. Despite the initial successes of immunotherapy, a low objective response rate due to resistance is still the main challenge in solid tumors, particularly advanced-stage lung cancer. One manifestation of tumor-immune dynamics is a release of soluble immune checkpoints and regulators to the surrounding microenvironment and circulation, the biological role of which has yet to be revealed. However, many studies highlight the clinical significance of soluble molecules such as sPD-1 and sLAG3.

A holistic snapshot of circulating immune checkpoints and regulators along the course of cancer progression can provide insights into the crosstalk between the immune system and a progressing tumor. Simultaneously capturing those circulating molecules can also establish tumor behavior predictions in response to immune checkpoint inhibitors. In the study presented here, pretreatment sera from 123 advanced-stage non-small cell lung cancer (NSCLC) patient samples receiving PD-1/PD-L1 targeted therapy was profiled with a panel of 31 immune checkpoint molecules.

Join this webinar to learn how research evaluating multiple soluble immune checkpoints in serum may help identify those likely to benefit from PD-1/PD-L1 immunotherapy and may reveal new immunotherapy targets for future investigation.

During this webinar viewers will:

• Learn why analyzing multiple circulating immune checkpoint molecules is critical to understanding tumor progression
• Discover which soluble immune checkpoint proteins correlated with NSCLC outcomes in this study
• Gain insights into the advantages of using a large multiplex immunoassay to test research samples
• Have the opportunity to ask questions during the live broadcast.

*For Research Use Only. Not For Use In Diagnostic Procedures.

This webinar will last for approximately 60 minutes.

Ever-increasing genomic information and advances in diagnostic technology continue to improve precision medicine, providing patients with the therapies most likely to successfully treat their cancers. While liquid biopsies are now broadly used to assess leukemias and lymphomas, many solid tumors still require the analysis of a tissue sample for biomarkers before therapy determination or as therapy resistance emerges. Limited tumor tissue often poses a challenge for molecular and anatomical pathologists, leading them to practice “tissue stewardship” as they seek to reveal the most information about a tumor from the smallest amount of tissue.

This panel discussion will describe optimal tissue sample handling as well as the pros and cons of using different technologies such as next-generation sequencing, immunohistochemistry, and PCR. Panel experts will describe their experience in determining the best sequence of assays based on the patient’s cancer type, stage, and more.

During this webinar, viewers will:

• Hear about best practices for specimen handling
• Gain insight into preanalytic variables that will impact assay-technology selection and likelihood of assay success
• Learn about the advantages and disadvantages of different tumor-profiling technologies
• Have an opportunity to ask questions during the live broadcast.

This webinar will last for approximately 60 minutes.